Yubin Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yubin Cai has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Traverso
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
3 shared publications - Anantha P. Chandrakasan
Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, USA
2 shared publications - Injoo Moon
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
2 shared publications - Saransh Sharma
Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA
2 shared publications - Zhenming Yang
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
2 shared publications - A. Alexiev
Division of Gastroenterology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by Springer Nature in Nature Electronics
- Vol. 9 (8) , 956-968
A miniaturized ingestible temperature sensor for continuous internal monitoring
Ingestible electronic systems offer a minimally invasive means to continuously monitor core body temperature, providing critical insights into a range of health conditions. However, the size of ingestible sensors often limits their use, particularly in paediatric populations. Here we report a miniaturized ingestible temperature sensor for continuous internal monitoring. The device integrates a 1 mm × 1 mm low-power (10 nW) integrated circuit, a 5 mm × 5 mm antenna for wireless backscatter communication and a coin-cell battery. The fully encapsulated system measures just 6 mm in diameter and 4 mm in height, dimensions aligned with those of US Food and Drug Administration-approved osmotic controlled-release oral delivery system and smaller than video capsule endoscopy devices, thus minimizing the risk of gastrointestinal retention. We evaluate the sensor in swine models under diverse physiological and pathophysiological conditions. This includes use in ambulatory multi-day monitoring, scenarios with inflammation-induced altered gastrointestinal transit and deployment alongside intravascular devices for vascular navigation and guidance.
- 15 June 2026
- Published by Springer Nature in Nature Electronics
- Vol. 9 (8) , 956-968
Open AccessA miniaturized ingestible temperature sensor for continuous internal monitoring
Ingestible electronic systems offer a minimally invasive means to continuously monitor core body temperature, providing critical insights into a range of health conditions. However, the size of ingestible sensors often limits their use, particularly in paediatric populations. Here we report a miniaturized ingestible temperature sensor for continuous internal monitoring. The device integrates a 1 mm × 1 mm low-power (10 nW) integrated circuit, a 5 mm × 5 mm antenna for wireless backscatter communication and a coin-cell battery. The fully encapsulated system measures just 6 mm in diameter and 4 mm in height, dimensions aligned with those of US Food and Drug Administration-approved osmotic controlled-release oral delivery system and smaller than video capsule endoscopy devices, thus minimizing the risk of gastrointestinal retention. We evaluate the sensor in swine models under diverse physiological and pathophysiological conditions. This includes use in ambulatory multi-day monitoring, scenarios with inflammation-induced altered gastrointestinal transit and deployment alongside intravascular devices for vascular navigation and guidance.
- 28 January 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Solid-State Circuits
- Vol. 61 (3) , 1082-1095
A Fully-Integrated Wireless Ingestible CMOS Drug-Delivery Chip With Electrochemical Energy Harvesting and pH-Adaptive MPPT for Personalized Therapeutics
The rapid growth of personalized medicine has driven increased demand for battery-free, energy-efficient ingestible electronics for on-demand gastrointestinal (GI) drug delivery. This article presents the first fully-integrated, battery-free ingestible CMOS platform that harvests energy from a galvanic cell (GC) through a reconfigurable switched-capacitor converter, with pH-adaptive maximum power point tracking (MPPT) guided by on-chip gastric pH measurement. The system offers three clinically relevant drug-delivery modes, selectable via 13.56 MHz wireless RF commands: burst, low-energy dissolve, and balanced modes. Upon receiving a drug-delivery command, the system applies an optimal voltage bias according to the measured pH and selected delivery mode, to electrochemically dissolve a metal membrane and release the payload. Fabricated in a 65-nm CMOS, the 6-mm2 chip integrates with a drug-delivery chamber, GC, and off-chip antenna to form a capsule that fits within the dimensions of commercial ingestible electronics. Ex vivo and in vitro tests demonstrate reliable system operation, with a 6-cm RF detection range from the tissue surface, 0.32-pH sensor resolution, and 72% end-to-end energy-harvesting efficiency with a wide range of input powers from 30 to $200~\mu $ W. By integrating pH-adaptive MPPT with RF-controlled multimode drug release on a single platform, this work advances adaptable, responsive, and patient-specific therapies for GI drug delivery.
- 28 January 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Solid-State Circuits
- Vol. 61 (3) , 1082-1095
A Fully-Integrated Wireless Ingestible CMOS Drug-Delivery Chip With Electrochemical Energy Harvesting and pH-Adaptive MPPT for Personalized Therapeutics
The rapid growth of personalized medicine has driven increased demand for battery-free, energy-efficient ingestible electronics for on-demand gastrointestinal (GI) drug delivery. This article presents the first fully-integrated, battery-free ingestible CMOS platform that harvests energy from a galvanic cell (GC) through a reconfigurable switched-capacitor converter, with pH-adaptive maximum power point tracking (MPPT) guided by on-chip gastric pH measurement. The system offers three clinically relevant drug-delivery modes, selectable via 13.56 MHz wireless RF commands: burst, low-energy dissolve, and balanced modes. Upon receiving a drug-delivery command, the system applies an optimal voltage bias according to the measured pH and selected delivery mode, to electrochemically dissolve a metal membrane and release the payload. Fabricated in a 65-nm CMOS, the 6-mm2 chip integrates with a drug-delivery chamber, GC, and off-chip antenna to form a capsule that fits within the dimensions of commercial ingestible electronics. Ex vivo and in vitro tests demonstrate reliable system operation, with a 6-cm RF detection range from the tissue surface, 0.32-pH sensor resolution, and 72% end-to-end energy-harvesting efficiency with a wide range of input powers from 30 to $200~\mu $ W. By integrating pH-adaptive MPPT with RF-controlled multimode drug release on a single platform, this work advances adaptable, responsive, and patient-specific therapies for GI drug delivery.
- 22 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Robotics
- Vol. 10 (107) , eadx1367
An ingestible capsule for luminance-based diagnosis of mesenteric ischemia
Acute mesenteric ischemia (AMI) results from insufficient blood flow to the intestines, leading to tissue necrosis with high morbidity and mortality. Diagnosis is often delayed because of nonspecific symptoms that mimic common gastrointestinal conditions. Current diagnostic methods, such as computed tomography and mesenteric angiography, are complex, costly, and invasive, highlighting the need for a rapid, accessible, and minimally invasive alternative. Here, we present FIREFLI (finding ischemia via reflectance of light), a bioinspired, ingestible capsule designed for luminance-based diagnosis of AMI. Upon ingestion, the device activates in the small intestine’s pH environment, emitting pulses from three radially spaced white light-emitting diodes and measuring reflected light across 10 wavelengths. FIREFLI then computes a tissue luminance biomarker, which outperforms color-change biomarkers because of superior intrasubject consistency. The diagnosis is processed onboard and wirelessly transmitted to an external mobile device. In vivo studies in swine ( n = 9) demonstrated a diagnostic accuracy of 90%, with a sensitivity of 98% and specificity of 85%. By providing a noninvasive, real-time diagnostic solution, FIREFLI has the potential to facilitate earlier detection and treatment of AMI, ultimately improving patient outcomes.
- 22 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Robotics
- Vol. 10 (107) , eadx1367
An ingestible capsule for luminance-based diagnosis of mesenteric ischemia
Acute mesenteric ischemia (AMI) results from insufficient blood flow to the intestines, leading to tissue necrosis with high morbidity and mortality. Diagnosis is often delayed because of nonspecific symptoms that mimic common gastrointestinal conditions. Current diagnostic methods, such as computed tomography and mesenteric angiography, are complex, costly, and invasive, highlighting the need for a rapid, accessible, and minimally invasive alternative. Here, we present FIREFLI (finding ischemia via reflectance of light), a bioinspired, ingestible capsule designed for luminance-based diagnosis of AMI. Upon ingestion, the device activates in the small intestine’s pH environment, emitting pulses from three radially spaced white light-emitting diodes and measuring reflected light across 10 wavelengths. FIREFLI then computes a tissue luminance biomarker, which outperforms color-change biomarkers because of superior intrasubject consistency. The diagnosis is processed onboard and wirelessly transmitted to an external mobile device. In vivo studies in swine ( n = 9) demonstrated a diagnostic accuracy of 90%, with a sensitivity of 98% and specificity of 85%. By providing a noninvasive, real-time diagnostic solution, FIREFLI has the potential to facilitate earlier detection and treatment of AMI, ultimately improving patient outcomes.